Electron Capital Partners Has Trimmed Exelon (EXC) Stake by $8.89 Million; Share Price Rose; As Array Biopharma (ARRY) Share Price Declined, Cormorant Asset Management Has Cut Position

Exelon Corporation (NYSE:EXC) Logo

Cormorant Asset Management Llc decreased its stake in Array Biopharma Inc (ARRY) by 4.47% based on its latest 2018Q1 regulatory filing with the SEC. Cormorant Asset Management Llc sold 31,257 shares as the company’s stock declined 10.53% with the market. The hedge fund held 668,743 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $10.91 million, down from 700,000 at the end of the previous reported quarter. Cormorant Asset Management Llc who had been investing in Array Biopharma Inc for a number of months, seems to be less bullish one the $3.38B market cap company. The stock increased 1.26% or $0.2 during the last trading session, reaching $16.04. About 1.59M shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 92.14% since May 31, 2017 and is uptrending. It has outperformed by 79.57% the S&P500.

Jos Shaver decreased its stake in Exelon Corp (EXC) by 14.24% based on its latest 2018Q1 regulatory filing with the SEC. Electron Capital Partners Llc sold 227,959 shares as the company’s stock rose 6.94% while stock markets declined. The hedge fund run by Jos Shaver held 1.37M shares of the power generation company at the end of 2018Q1, valued at $53.55 million, down from 1.60M at the end of the previous reported quarter. Electron Capital Partners Llc who had been investing in Exelon Corp for a number of months, seems to be less bullish one the $39.79 billion market cap company. The stock increased 1.25% or $0.51 during the last trading session, reaching $41.22. About 6.73 million shares traded or 13.05% up from the average. Exelon Corporation (NYSE:EXC) has risen 12.88% since May 31, 2017 and is uptrending. It has outperformed by 0.31% the S&P500.

Investors sentiment increased to 1.74 in Q1 2018. Its up 0.44, from 1.3 in 2017Q4. It increased, as 16 investors sold ARRY shares while 54 reduced holdings. 55 funds opened positions while 67 raised stakes. 189.71 million shares or 2.27% less from 194.11 million shares in 2017Q4 were reported. American And Management Co holds 0% or 100 shares. Strs Ohio reported 21,100 shares stake. North Star Invest Mgmt Corp has invested 0.14% in Array BioPharma Inc. (NASDAQ:ARRY). Renaissance Ltd Liability Com invested in 472,952 shares. Loring Wolcott Coolidge Fiduciary Limited Liability Partnership Ma has invested 0% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Macquarie Gp Inc reported 0.02% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Alyeska Invest Lp owns 173,438 shares for 0.03% of their portfolio. Baker Bros Ltd Partnership stated it has 0.78% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Geode Capital Mgmt Ltd Liability has 1.98 million shares for 0.01% of their portfolio. Nj State Employees Deferred Compensation Plan, a New Jersey-based fund reported 20,000 shares. Global X Management Ltd, New York-based fund reported 3,654 shares. Fisher Asset Ltd owns 0% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 226,603 shares. Farallon Management Limited Liability stated it has 3.10 million shares or 0.35% of all its holdings. American Int reported 0.01% in Array BioPharma Inc. (NASDAQ:ARRY). Moreover, Alliancebernstein Ltd Partnership has 0.01% invested in Array BioPharma Inc. (NASDAQ:ARRY).

Analysts await Array BioPharma Inc. (NASDAQ:ARRY) to report earnings on August, 8. They expect $-0.25 earnings per share, down 47.06% or $0.08 from last year’s $-0.17 per share. After $-0.11 actual earnings per share reported by Array BioPharma Inc. for the previous quarter, Wall Street now forecasts 127.27% negative EPS growth.

Since December 16, 2017, it had 0 insider purchases, and 10 insider sales for $16.60 million activity. 156,016 shares were sold by Sandor Victor, worth $2.76 million on Friday, March 9. Shares for $102,975 were sold by Haddock Jason on Tuesday, January 16. 819,671 shares valued at $8.90M were sold by Squarer Ron on Saturday, December 16. $3.03M worth of Array BioPharma Inc. (NASDAQ:ARRY) was sold by Robbins Andrew R.

Among 10 analysts covering Array BioPharma (NASDAQ:ARRY), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Array BioPharma had 38 analyst reports since June 3, 2016 according to SRatingsIntel. On Tuesday, February 6 the stock rating was maintained by SunTrust with “Buy”. The firm has “Buy” rating given on Wednesday, August 9 by Stifel Nicolaus. The rating was maintained by Cowen & Co with “Buy” on Sunday, January 21. Jefferies maintained it with “Buy” rating and $900 target in Thursday, July 13 report. As per Wednesday, September 20, the company rating was maintained by Piper Jaffray. Cowen & Co maintained it with “Buy” rating and $15.0 target in Tuesday, October 31 report. Cantor Fitzgerald maintained the shares of ARRY in report on Tuesday, July 18 with “Buy” rating. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Cantor Fitzgerald on Tuesday, May 30. The rating was maintained by Leerink Swann on Monday, September 26 with “Outperform”. The firm has “Buy” rating given on Tuesday, October 31 by Piper Jaffray.

Cormorant Asset Management Llc, which manages about $841.40 million and $1.34 billion US Long portfolio, upped its stake in Apellis Pharmaceuticals Inc by 319,472 shares to 4.09 million shares, valued at $90.39M in 2018Q1, according to the filing. It also increased its holding in Gemphire Therapeutics Inc by 241,635 shares in the quarter, for a total of 1.04 million shares, and has risen its stake in Nektar Therapeutics (Call) (NASDAQ:NKTR).

Another recent and important Array BioPharma Inc. (NASDAQ:ARRY) news was published by Profitconfidential.com which published an article titled: “ARRY Stock Is Now Primed for a Move Toward Higher Prices” on May 14, 2018.

Among 22 analysts covering Exelon Corporation (NYSE:EXC), 14 have Buy rating, 1 Sell and 7 Hold. Therefore 64% are positive. Exelon Corporation had 81 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Overweight” rating by JP Morgan on Tuesday, April 10. Citigroup initiated Exelon Corporation (NYSE:EXC) on Friday, September 18 with “Sell” rating. Credit Suisse downgraded Exelon Corporation (NYSE:EXC) rating on Wednesday, April 4. Credit Suisse has “Hold” rating and $4200 target. The stock of Exelon Corporation (NYSE:EXC) earned “Buy” rating by Jefferies on Tuesday, September 5. Suntrust Robinson upgraded the stock to “Buy” rating in Monday, September 14 report. On Wednesday, July 20 the stock rating was maintained by Citigroup with “Sell”. Morgan Stanley upgraded Exelon Corporation (NYSE:EXC) on Friday, November 18 to “Overweight” rating. The stock of Exelon Corporation (NYSE:EXC) earned “Buy” rating by Deutsche Bank on Friday, July 22. On Tuesday, January 2 the stock rating was maintained by Guggenheim with “Buy”. RBC Capital Markets maintained it with “Buy” rating and $40.0 target in Sunday, September 10 report.

Analysts await Exelon Corporation (NYSE:EXC) to report earnings on August, 1. They expect $0.59 earnings per share, up 9.26% or $0.05 from last year’s $0.54 per share. EXC’s profit will be $569.57M for 17.47 P/E if the $0.59 EPS becomes a reality. After $0.96 actual earnings per share reported by Exelon Corporation for the previous quarter, Wall Street now forecasts -38.54% negative EPS growth.

Electron Capital Partners Llc, which manages about $359.29M and $527.94M US Long portfolio, upped its stake in Aes Corp (NYSE:AES) by 3.21M shares to 3.83M shares, valued at $43.60 million in 2018Q1, according to the filing. It also increased its holding in Avangrid Inc by 343,899 shares in the quarter, for a total of 1.03M shares, and has risen its stake in Loma Negra Corp.

Since March 15, 2018, it had 0 buys, and 1 sale for $948,500 activity.

More notable recent Exelon Corporation (NYSE:EXC) news were published by: Seekingalpha.com which released: “Bloomberg: New Jersey governor set to sign nuclear bailout bill” on May 23, 2018, also Seekingalpha.com with their article: “Exelon (EXC) Q1 2018 Results – Earnings Call Transcript” published on May 02, 2018, Bizjournals.com published: “Baltimore-area companies fall short of Fortune 500 list” on May 29, 2018. More interesting news about Exelon Corporation (NYSE:EXC) were released by: Seekingalpha.com and their article: “Exelon Posts Strong Growth Figures In 1Q18” published on May 08, 2018 as well as Seekingalpha.com‘s news article titled: “Illinois nuclear subsidies supported by FERC, DoJ in court filing” with publication date: May 30, 2018.

Investors sentiment decreased to 1.04 in 2018 Q1. Its down 0.09, from 1.13 in 2017Q4. It dived, as 50 investors sold EXC shares while 252 reduced holdings. 86 funds opened positions while 228 raised stakes. 731.27 million shares or 0.49% more from 727.68 million shares in 2017Q4 were reported. 10,134 are held by Wesbanco Bancorporation Inc. Zurcher Kantonalbank (Zurich Cantonalbank) holds 612,917 shares. Boyd Watterson Asset Management Limited Liability Oh holds 0.33% in Exelon Corporation (NYSE:EXC) or 17,222 shares. Univest Of Pennsylvania reported 8,390 shares. Andra Ap reported 0.17% in Exelon Corporation (NYSE:EXC). Arvest Commercial Bank Division holds 0.02% of its portfolio in Exelon Corporation (NYSE:EXC) for 6,053 shares. Argyle Capital Management Inc holds 39,725 shares or 0.61% of its portfolio. Convergence Investment Partners Ltd Company reported 0.55% in Exelon Corporation (NYSE:EXC). Voya Mngmt Ltd holds 0.3% or 3.64 million shares in its portfolio. Qs Investors Limited Co reported 88,653 shares. Goldman Sachs Grp Incorporated holds 0.12% of its portfolio in Exelon Corporation (NYSE:EXC) for 12.43M shares. Twin Capital Mngmt Incorporated stated it has 0.45% of its portfolio in Exelon Corporation (NYSE:EXC). Atria Ltd Liability owns 9,942 shares for 0.02% of their portfolio. Wedge Mngmt L LP Nc has invested 0.11% in Exelon Corporation (NYSE:EXC). Moreover, Kepos Capital Lp has 0.3% invested in Exelon Corporation (NYSE:EXC).

Exelon Corporation (NYSE:EXC) Institutional Positions Chart